Literature DB >> 9548892

Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs.

K M Wasan1, S M Cassidy.   

Abstract

The plasma lipoprotein distribution of potential drug candidates is not commonly studied. For some hydrophobic drug candidates, attainment of similar plasma free drug levels has not been associated with uniform production of pharmacological activity in different animal species. It is well-known that plasma lipoprotein lipid profiles vary considerably between different animal species. In addition, human disease states can significantly influence plasma lipoprotein profiles, resulting in altered therapeutic outcomes. Current research has shown that lipoprotein binding of drug compounds can significantly influence not only the pharmacological and pharmacokinetic properties of the drug, but the relative toxicity as well. Elucidation of drug distribution among plasma lipoproteins is expected to yield valuable insight into factors governing the pharmacological activity and potential toxicity of the drug. This paper will present an historical perspective and summarize the latest research in the area of lipoprotein-drug interactions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548892     DOI: 10.1021/js970407a

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  43 in total

1.  Analysis of Drug Interactions with Lipoproteins by High-Performance Affinity Chromatography.

Authors:  Matthew R Sobansky; David S Hage
Journal:  Adv Med Biol       Date:  2012

Review 2.  Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A.

Authors:  Kishor M Wasan; Manisha Ramaswamy; Mona Kwong; Kathy D Boulanger
Journal:  AAPS PharmSci       Date:  2002

3.  Equivalence-by-design: targeting in vivo drug delivery profile.

Authors:  Mei-Ling Chen; Vincent H L Lee
Journal:  Pharm Res       Date:  2008-10-28       Impact factor: 4.200

4.  Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity.

Authors:  K M Wasan; R Subramanian; J W Chou; M Ramaswamy; P H Pritchard
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

5.  A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine.

Authors:  K M Wasan; S M Cassidy; M Ramaswamy; A Kennedy; F W Strobel; S P Ng; T Y Lee
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

6.  Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.

Authors:  René Holm; Christopher J H Porter; Anette Müllertz; Henning G Kristensen; William N Charman
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 7.  Studies of metabolite-protein interactions: a review.

Authors:  Ryan Matsuda; Cong Bi; Jeanethe Anguizola; Matthew Sobansky; Elliott Rodriguez; John Vargas Badilla; Xiwei Zheng; Benjamin Hage; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-11-25       Impact factor: 3.205

8.  Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.

Authors:  Daniel P Rossignol; Kishor M Wasan; Eugene Choo; Edwin Yau; Nancy Wong; Jeffrey Rose; Jeffrey Moran; Melvyn Lynn
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Analysis of drug interactions with high-density lipoprotein by high-performance affinity chromatography.

Authors:  Sike Chen; Matthew R Sobansky; David S Hage
Journal:  Anal Biochem       Date:  2009-10-13       Impact factor: 3.365

Review 10.  Characterization of drug-protein interactions in blood using high-performance affinity chromatography.

Authors:  David S Hage; Abby Jackson; Matthew R Sobansky; John E Schiel; Michelle J Yoo; K S Joseph
Journal:  J Sep Sci       Date:  2009-03       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.